Get the Stockscreener App
1.79
0.00%
0.00
Ocugen Inc stock is traded at $1.79, with a volume of 4.97M.
It is up +0.00% in the last 24 hours and down -7.73% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.79
Open:
$1.75
24h Volume:
4.97M
Relative Volume:
0.64
Market Cap:
$586.94M
Revenue:
$4.41M
Net Income/Loss:
$-67.85M
P/E Ratio:
-7.9274
EPS:
-0.2258
Net Cash Flow:
$-57.15M
1W Performance:
-8.67%
1M Performance:
-7.73%
6M Performance:
+1.13%
1Y Performance:
+159.80%
1-Day Range:
$1.72
$1.81
1-Week Range:
$1.72
$1.96
52-Week Range:
$0.57
$2.725
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.79 | 586.94M | 4.41M | -67.85M | -57.15M | -0.2258 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Initiated | Canaccord Genuity | Buy |
| Mar-11-26 | Initiated | Oppenheimer | Outperform |
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Hennion & Walsh Asset Management Inc. Invests $1.36 Million in Ocugen, Inc. $OCGN - MarketBeat
Earnings call transcript: Ocugen Q4 2025 reveals steady R&D investment By Investing.com - Investing.com
OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study - The Globe and Mail
OCGN Finishes Initial Participant Registration for Key Stargardt Disease Trial - Bitget
Ocugen Hits Key Milestone In GARDian3 Stargardt Gene Therapy Program - Sahm
Ocugen Achieves Key Enrollment Target in Stargardt Disease Gene Therapy Trial - AD HOC NEWS
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease - ir.ocugen.com
Ocugen completes dosing early in phase 2/3 GARDian3 trial for Stargardt disease - Ophthalmology Times
Ocugen (OCGN) Completes Dosing in Key Clinical Trial for Stargar - gurufocus.com
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of Ocu410st for Stargardt Disease - MarketScreener
Ocugen completes enrollment in Stargardt disease gene therapy trial By Investing.com - Investing.com India
Ocugen completes enrollment in Stargardt disease gene therapy trial - Investing.com
Ocugen wraps 63-patient Stargardt gene therapy dosing in 9 months - Stock Titan
Ocugen falls after 12-month data from mid-stage trial for GA therapy - MSN
Block Trades: What is the next catalyst for Ocugen IncEarnings Recap Report & Real-Time Market Trend Scan - baoquankhu1.vn
Ocugen, Inc. targets 100s of mutations with gene therapies to address 132 billion dollar vision loss burden - Traders Union
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
OCGN PE Ratio & Valuation, Is OCGN Overvalued - Intellectia AI
Ocugen (OCGN) Reveals OCU410 Clinical Trial Data - Insider Monkey
Ocugen, Inc. (NASDAQ:OCGN) Q3 2025 Earnings Call Transcript - MSN
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Retinal specialists drive clinical progress on modifier gene therapy, Ocugen, Inc. asserts - Traders Union
OCGN stock tanks after gene therapy trial update — what did Ocugen announce? - MSN
Ocugen (OCGN) price target increased by 11.11% to 10.20 - MSN
Ocugen Inc. (OCGN): One of the popular penny stocks on Robinhood - MSN
Risk Recap: Is Ocugen Inc undervalued by DCF analysisMarket Risk Summary & Weekly Return Optimization Alerts - baoquankhu1.vn
How The Ocugen (OCGN) Narrative Is Shifting With Retinal Gene Therapy Data And New Valuations - Yahoo Finance
Ocugen to Showcase Gene Therapy Advances at Upcoming Ophthalmology Conferences - MSN
Ocugen Completes Enrollment For Phase 3 Trial - Let's Data Science
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Vanguard (OCGN) disaggregates holdings; reports 0% ownership in Ocugen - Stock Titan
Can Ocugen succeed where other gene therapy makers have struggled? - Pharma Voice
Ocugen Updates Roadmap for Gene-Agnostic Retinal Therapies - TipRanks
What is Noble Financial's Estimate for Ocugen Q3 Earnings? - MarketBeat
HC Wainwright Issues Positive Forecast for Ocugen Earnings - MarketBeat
Ocugen posts investor presentation outlining progress across three gene-therapy BLAs, Phase 3 enrollment and positive Phase 2/3 data - TradingView
Ocugen (OCGN) showcases retinal gene therapy pipeline with new OCU410 Phase 2 data - Stock Titan
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen appoints Rita Johnson-Greene as chief financial officer - MSN
Ocugen (NASDAQ:OCGN) Given "Buy" Rating at Chardan Capital - MarketBeat
Ocugen (OCGN) Stock Maintained at Buy Rating by Chardan Capital - GuruFocus
Ocugen Shares Drop as Eye Disease Gene Therapy Shows Delays in Phase II Trial - Bitget
Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study - The Globe and Mail
Noble Capital raises Ocugen stock price target on phase 2 results By Investing.com - Investing.com Australia
Noble Capital raises Ocugen stock price target on phase 2 results - Investing.com UK
H.C. Wainwright raises Ocugen stock price target on gene therapy data - Investing.com India
Ocugen Lines Up Phase III Macular Degeneration Study For Gene Therapy OCU410 - Citeline News & Insights
OCGN: HC Wainwright & Co. Raises Price Target to $10.00, Maintai - GuruFocus
Ocugen’s GA gene therapy garners mixed sentiments on 12-month Phase II readout - Yahoo Finance
H.C. Wainwright raises Ocugen stock price target on gene therapy data By Investing.com - Investing.com Australia
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.49%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):